Phase 2 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to give written consent and are willing to follow the trial schedule and requirements
• People aged 18 to 75 years old
• People who have been diagnosed with rectal adenocarcinoma (a specific type of rectal cancer), confirmed through laboratory testing of tissue
• People whose cancer has been tested and shown to have a specific molecular profile (known as pMMR, MSI-L, or MSS) through laboratory methods (confirm with trial site)
• People whose tumor is located within 3 cm of a specific part of the lower bowel (the dentate line), as confirmed by colonoscopy, physical examination, or MRI scan
• People whose cancer is at an early-to-moderate stage (cT1–3, N0–1, M0) as assessed by MRI, meaning it has not spread to distant parts of the body
• People whose tumor has been assessed by the trial doctor as able to be surgically removed
• People who have not yet received any treatment for their rectal cancer
• People who are generally well enough to carry out daily activities with little or no limitation (confirmed by a standard medical performance scale)
• People whose organ function (such as liver, kidneys, and blood) meets the required levels
• Women who could become pregnant must have a negative pregnancy blood test within 72 hours before starting the trial, and must agree to use highly effective contraception during the trial and for 120 days after the last dose; men whose partners could become pregnant must either have had a sterilisation procedure or agree to use highly effective contraception during the trial and for 120 days after the last dose

Who may not be able to join:

• People whose rectal cancer is confirmed as a poorly differentiated, undifferentiated, mucinous, or signet ring cell type of adenocarcinoma
• People who have already received treatment for rectal cancer, or whose cancer has spread to other parts of the body
• People whose MRI scan shows certain high-risk features, including involvement of the surrounding tissue boundary, spread into nearby blood or lymph vessels, more advanced lymph node involvement, positive lateral lymph nodes, or a deeper level of tumour spread into surrounding fat (confirm with trial site for specific terms)
• People who have, or are at high risk of, a blockage, tear, or bleeding in the bowel
• People for whom long-course radiotherapy is not medically appropriate
• People who are not well enough to undergo surgery
• People who have two or more colorectal cancer tumours at the same time
• People who cannot have an MRI scan for any reason
• People who have had, or currently have, another type of cancer
• People who have an active autoimmune disease that has required ongoing medical treatment within the past 2 years
• People who have HIV infection
• People who have untreated chronic hepatitis B, or carry the hepatitis B virus with levels above a certain threshold, or have active hepatitis C with detectable virus in the blood
• People who have a known allergy or sensitivity to any of the trial medicines (tislelizumab, capecitabine, or oxaliplatin) or their components
• People who, in the trial doctor's judgement, do not meet the trial requirements for any other reason

Important: Always verify eligibility with the trial site directly before applying.